Introduction
============

Breast cancer is a malignant disease that affects women worldwide. In the United States, breast cancer was estimated to account for 29% of all new cancer cases and 15% of all cancer-related mortality among women in 2014 ([@b1-mmr-16-04-4671]). The major cause of these mortalities was not the primary breast cancer tumor, but the metastases at distant sites; in most patients with breast cancer, the tumor was able to metastasize to different organs, such as bone, lungs and brain ([@b2-mmr-16-04-4671]--[@b4-mmr-16-04-4671]). In a number of patients, breast cancer has been demonstrated to be aggressive and metastasized to a distant site a short time following the detection of primary tumor, whereas in other cases the hallmark of metastases may not be evident for a longer period ([@b5-mmr-16-04-4671]). This feature makes it difficult to identify the risk factors of breast cancer metastasis and to evaluate relevant curative therapies ([@b5-mmr-16-04-4671]). Although mammographic screening may lower the metastasis-related mortality, the method is inappropriate for detection at early stages ([@b6-mmr-16-04-4671]). Therefore, it is urgent to develop effective molecular techniques for the diagnosis and treatment of breast cancer metastasis.

The initial event of metastasis may be the transformation of normal breast stromal cells to cells with oncogenic mutations. The subsequent generation of cancer stromal cells may lead to poor prognosis, as a self-renewing population of stromal cells accumulates the mutations required for tumorigenesis ([@b7-mmr-16-04-4671]). In the transforming growth factor β receptor 2 knockout mouse model, stromal fibroblasts were reported to be a major source of elevated TGFβ expression, which was used to predict early breast cancer metastasis ([@b8-mmr-16-04-4671]). Therefore, breast cancer stromal cells may be considered as attractive therapeutic targets. At present, several molecular targeting therapies have been developed; for example, agents targeting HER2 (such as trastuzumab) have been used to treat patients with metastatic breast cancer in which *HER2* is overexpressed ([@b9-mmr-16-04-4671]). P38 mitogen-activated protein kinase has been reported to inhibit breast cancer metastasis through the regulation of stromal expansion ([@b10-mmr-16-04-4671]). In addition, breast cancer metastasis-suppressor 1 was demonstrated to suppress metastasis in multiple organs, such as breast and ovary, by blocking several of the steps involved in the metastatic process ([@b11-mmr-16-04-4671]); however, it was apparently insufficient to use only one gene as a targeted therapy due to the complex pathogenesis of cancer metastasis. Therefore, an improved understanding of the molecular mechanisms of metastasis is required to discover as yet unknown target genes.

The present study analyzed expression profile microarray data GSE8977 from the Gene Expression Omnibus (GEO) database, which contained stroma samples from normal and invasive ductal carcinoma (IDC) breast tissue samples, to perform bioinformatics analyses, including differential analysis, enrichment analysis and protein-protein interaction (PPI) network analysis. The present study aimed to identify potentially important gene markers and to gain better insight into the molecular mechanism of breast cancer metastasis.

Materials and methods
=====================

### Microarray data

Expression profile GSE8977 was obtained from National Center of Biotechnology Information GEO database (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8977>) ([@b12-mmr-16-04-4671]). The profile comprised 22 stroma samples, of which 15 were from normal breast samples (Control group) and 7 were from IDC tumor samples (Tumor group), and was based on the GPL570 platform data (Affymetrix Human Genome U133 Plus 2.0 Array).

### Data preprocessing

Raw data underwent preprocessing, such as background correction, quantile normalization and probe summarization, using the robust multi-array average algorithm ([@b13-mmr-16-04-4671]) and the 'affy' package version 1.54.0 (<http://www.bioconductor.org/packages/release/bioc/html/affy.html>) in Bioconductor, as previously described ([@b14-mmr-16-04-4671]), and a gene expression matrix was obtained.

### Differently expressed gene (DEG) selection

Empirical Bayes test was used to identify DEGs between the two groups, based on the Linear Models for Microarray Analysis ('limma') package version 3.32.2 of R (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>) ([@b15-mmr-16-04-4671]). The selection criteria for significant DEGs were \|log2 fold-change\| ≥1 and a false discovery rate (FDR)-adjusted P-value \<0.05.

### Enrichment analysis of DEGs

Function enrichment analysis of the identified DEGs was performed with the Gene Ontology (GO) database (<http://www.geneontology.org>) ([@b16-mmr-16-04-4671]), which included functions on biological process, molecular function and cellular component. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<http://www.genome.jp/kegg/pathway.html>) was used to identify significantly enriched pathways ([@b17-mmr-16-04-4671]). The threshold for significant GO terms and KEGG pathways was P\<0.01, based on hypergeometric distribution.

### Functional annotation of the corresponding DEGs

The identified DEGs were combined with information from the TRANScription FACtor (TRANSFAC) database version 7.0 (<http://www.gene-regulation.com/pub/databases.html>) to analyze their potential transcriptional functions and to reveal which were potential transcription factors (TFs). Oncogenes and tumor suppressor (TS) genes were also screened using the TS database (<http://bioinfo.mc.vanderbilt.edu/TSGene/>) version 2.0 ([@b18-mmr-16-04-4671]) and the Tumor Associated Genes (TAGs) database (<http://www.binfo.ncku.edu.tw/TAG/>) ([@b19-mmr-16-04-4671]).

### Construction of a PPI network and subnetwork

To explore potential interactions of the DEGs on the protein level and to establish a PPI network, DEGs were mapped with the Search Tool for the Retrieval of Interacting Genes (STRING) database version 10.5 (<http://string-db.org>) ([@b20-mmr-16-04-4671]), with the criterion of a combined score ≥0.9. Only the PPIs that were validated by previous experiments or co-expression analysis, or recorded in relevant databases were screened out to construct the network. In addition, it was required that at least one gene in each PPI should be an identified DEG. Finally, the PPI network was visualized using Cytoscape version 3.5.1 (<http://cytoscape.org>) software ([@b21-mmr-16-04-4671]).

The BioNet tool (<http://www.bioconductor.org/packages/release/bioc/html/BioNet.html>) version 1.36.0 in R was used to extract the subnetwork, based on significant P-values of DEGs ([@b22-mmr-16-04-4671]). FDR-adjusted P\<0.0001 was chosen as the cut-off value for subnetwork extraction. KEGG pathway enrichment analysis was performed to reveal potential pathways for genes in the subnetwork, using the aforementioned criterion.

Results
=======

### Analysis of DEGs

Based on the selection criteria, a total of 910 transcripts were identified to be differentially expressed between the two groups, 347 of which were upregulated and 563 were downregulated. These transcripts corresponded to 84 upregulated genes and 150 downregulated genes, giving a total of 234 identified DEGs.

### KEGG pathway and GO functional enrichment analyses

KEGG pathway enrichment analysis indicated that the downregulated DEGs were enriched in immune response-related pathways, including *Staphylococcus aureus* infection, allograft rejection and graft-versus-host disease pathways, as well as pathways related to cell differentiation and cell adhesion, such as hematopoietic cell lineage, osteoclast differentiation and cell adhesion molecules. The upregulated DEGs were enriched in cancer-related pathways, including colorectal, endometrial and thyroid cancer pathways, as well as the adherens junction pathway ([Table I](#tI-mmr-16-04-4671){ref-type="table"}).

To gain further insight into the function of the identified DEGs, GO analysis was performed ([Table II](#tII-mmr-16-04-4671){ref-type="table"}). The downregulated DEGs were revealed to be highly related to immunoreactions, such as activation of immune response, leukocyte migration and positive regulation of leukocyte activation; additional functions included cell adhesion and protein secretion. The upregulated DEGs were mainly enriched in cell proliferation- and tissue development-related functions, such as muscle cell proliferation, regulation of epithelial cell proliferation and tissue development; as well as cell adhesion-related processes such as regulation of focal adhesion assembly.

### Functional annotation of TFs and TAGs

The identified DEGs were analyzed for potential functions as TFs and TAGs ([Table III](#tIII-mmr-16-04-4671){ref-type="table"}). The analysis indicated that, of the downregulated DEGs, 3 were identified as TFs and 12 as TAGs; of the upregulated DEGs, 6 were indicated to be TFs and 17 were TAGs.

### PPI network of the DEGs

DEGs were integrated with interactions from the STRING database, and a PPI network was constructed ([Fig. 1](#f1-mmr-16-04-4671){ref-type="fig"}). The top 10 nodes with the highest degrees in the PPI network included: epidermal growth factor receptor (EGFR), degree=94; CD4, degree=43; lymphocyte cytosolic protein 2 (LCP2), degree=28; hematopoietic cell kinase (HCK), degree=22; integrin β2 (ITGB2), degree=21; interferon regulatory factor 1 (IRF1), degree=21; C-X-C motif chemokine 10 (CXCL10), degree=20; protachykinin 1 (TAC1), degree=18; TYRO protein tyrosine kinase-binding protein (TYROBP), degree=18; and C-C motif chemokine 2 (CCL2), degree=16. EGFR exhibited the highest degree, which suggested that it may serve a predominant role in breast cancer metastasis.

### Subnetwork and KEGG functional analysis of DEGs

To further explore the key nodes for breast cancer metastasis, a subnetwork was established comprising 44 nodes using the BioNet tool, among which spleen tyrosine kinase (SYK) was predominant with the highest degree (degree=10; [Fig. 2](#f2-mmr-16-04-4671){ref-type="fig"}). KEGG pathway enrichment analysis indicated that proteins in the subnetwork, in which SYK was central, were involved in immune response pathways, such as *Staphylococcus aureus* infection, natural killer cell-mediated cytotoxicity and B cell receptor signaling pathway; as well as cell differentiation and cell adhesion pathways, including osteoclast differentiation and cell adhesion molecules ([Table IV](#tIV-mmr-16-04-4671){ref-type="table"}).

Discussion
==========

The present study analyzed differential gene expressions, protein-protein interactions and GO term and KEGG pathway enrichment of the microarray profile GSE8977, and identified a total of 234 DEGs between normal and IDC breast tumor samples. The DEGs were revealed to be related to immune response, cell adhesion, proliferation and development-related functions and pathways. In addition, EGFR and SYK were identified as hub nodes in the PPI network or the subnetwork, respectively. Of the downregulated DEGs, three were identified as TFs, including *SPI1*, lymphoid enhancer-binding factor 1 (*LEF1*) and pre-B-cell leukemia homeobox 3 (*PBX3*), of which *SPI1* is a known oncogene; two other downregulated genes, capping actin protein, gelsolin like (*CAPG*) and tumor protein p53-inducible nuclear protein 1 (*TP53INP1*), were identified as TS genes. The upregulated DEGs also included TFs and TS genes, such as transcription factor 7-like 2 (*TCF7L2*) and pleiomorphic adenoma gene-like 1 (*PLAGL1*).

During the process of breast cancer metastasis, it is essential for the invasion of tumor cells to cause changes of cell adhesion, which allows them to invade into the surrounding host tissues ([@b6-mmr-16-04-4671]). Thus, it is speculated that alteration of the genes and/or proteins that participate in cell adhesion or immune-related processes may have an influence on metastasis. A previous study has demonstrated that CAPG protein expression may inhibit tumorigenesis since they were lost at the stage of tumorigenesis in certain cancer cell lines, thus it has been proposed to be a TS gene ([@b23-mmr-16-04-4671]). It has recently been reported as a potential biomarker for bone metastasis in breast cancer ([@b24-mmr-16-04-4671]). These results are confirmed by the present findings, which demonstrated that its expression was downregulated and was regarded as a TS gene in breast cancer metastasis. *TP53INP1* is another downregulated TS gene identified by the present study, which has been reported to be associated with inflammation diseases ([@b25-mmr-16-04-4671]). The expression level of *TP53INP1* was negatively associated with parameters such as tumor size, high histological grade, lymph node metastasis and aberrant p53 expression ([@b26-mmr-16-04-4671]). *TP53INP1* may suppress breast carcinoma since it was regulated by microRNA-34a which is a known suppressor of metastasis ([@b27-mmr-16-04-4671]).

Previous *in vivo* experiments have verified that the downregulation of *PBX3* expression was able to suppress tumor growth and metastases ([@b28-mmr-16-04-4671]). *LEF1* has been associated with the regulation of cell proliferation, and human breast cancer cells transfected with *LEF1* small interfering RNA resulted in a significant arrest at the G2/M phase of the cell cycle ([@b29-mmr-16-04-4671]). *SPI1* has been reported to be crucial for the differentiation or activation of macrophages or B cells ([@b30-mmr-16-04-4671]). Macrophages and B cells are involved in differentiation and immune-related processes, and they are found in the tumor microenvironment ([@b30-mmr-16-04-4671]), thus may influence tumor progression. It may be inferred that the aforementioned TFs serve significant roles in breast cancer metastasis, and these roles may be through their involvement in the immune response. However, their potential targets need to be further explored.

Cell adhesion and proliferation are important processes that are associated with metastasis of various cancers ([@b31-mmr-16-04-4671],[@b32-mmr-16-04-4671]). *PLAGL1* is a zinc-finger nuclear transcription factor that that has been reported to be involved in cellular proliferation in various cancer types ([@b33-mmr-16-04-4671]). Enrichment analysis of the present study identified *PLAGL1* as highly associated with the regulation of epithelial cell proliferation, which implied that it may participate in this function and, thus, may influence breast cancer metastasis. *TCF7L2* has been implicated in colorectal cancer ([@b34-mmr-16-04-4671]). The T cell factor/β-catenin protein complex is oncogenic and serves significant roles in regulating cell adhesion, and *TCF7L2* acts as an antagonist of this complex, which suggested the importance of *TCF7L2* in cancer as a TS gene involved in cell adhesion. Notably, although the present study predicted *TCF7L2* as a TS gene, its expression was revealed to be upregulated. On this basis, it was speculated that during breast cancer metastasis, *TCF7L2* may serve a specific and different role compared with other, downregulated, TS genes. However, the inhibitory effects on metastasis by the upregulation of *TCF7L2* expression may be small compared with the oncogenic roles of other genes. Nevertheless, it is likely that disturbed function of cell adhesion by *TCF7L2* might be important in the metastasis of breast cancer.

EGFR is a member of the type 1 family of cell surface receptor tyrosine kinases that has been correlated with numerous cancer types, including breast cancer ([@b35-mmr-16-04-4671]). In addition, *EGFR* was demonstrated to be highly expressed in breast tumor cells with lymph node metastasis ([@b36-mmr-16-04-4671]). Ephrin type-A receptor 2 (EPHA2) is a member of the Eph-receptor family and is commonly overexpressed in many types of cancers and contributes to the metastasis ([@b37-mmr-16-04-4671]). EphA2 was reported to be induced by cell adhesion, and this increased expression was revealed to be dependent on the activation of EGFR ([@b37-mmr-16-04-4671]). This result suggested the potential involvement of EGFR in cell adhesion. Combining these previous findings with the enrichment analysis of the present study, which demonstrated that *EGFR* was an upregulated oncogene with the highest degree in the PPI network, it may be hypothesized that for breast cancer metastasis, *EGFR* may might exert its function by affecting cell adhesion, and high levels of *EGFR* expression may be used as a strong prognosis gene.

SYK is a protein tyrosine kinase that is widely expressed in hematopoietic cells, and has been reported to have a close association with leukemia ([@b38-mmr-16-04-4671]) and lymphoma ([@b39-mmr-16-04-4671]). *SYK* expression was previously demonstrated to be common in normal human breast tissue; however its expression is low or undetectable in invasive breast carcinoma. In addition, SYK was revealed to function as a TS gene in breast cancer by reducing cell motility and invasion ([@b40-mmr-16-04-4671]). Conversely, loss of *SYK* expression was reported to be associated with increased cellular invasiveness ([@b41-mmr-16-04-4671]). Expression and signaling activity of *SYK* represents a favorable prognostic factor in breast cancer ([@b42-mmr-16-04-4671]). *SYK*-regulated genes are important for breast cancer metastasis, as they may regulate immune responses, cell differentiation and cell adhesion pathways, which suggested that *SYK* may be used as an effective inhibitor for breast cancer metastasis.

In conclusion, the present study used a series of bioinformatics analyses to provide potential biomarkers such as *CAPG*, *TP53INP1*, *SPI1*, *LEF1*, *PBX3*, *TCF7L2*, *PLAGL1*, *EGFR* and *SYK* for breast cancer metastasis. Many of these DEGs such as *LEF1, SPI1, PLAGL1* and *TCF7L2* were associated with cell adhesion, cellular proliferation or the immune response and may influence the metastasis of breast cancer through the regulation of these function or pathways. However, these predictions require validation by *in vitro* and *in vivo* experiments. This study provides novel insights for breast cancer metastasis and suggests promising targets for inhibiting breast cancer metastasis.

![Predicted protein-protein interaction network of DEGs in breast cancer metastasis. Red nodes represent upregulated DEGs; green nodes represent downregulated DEGs; and yellow nodes represent genes that were not identified as differentially expressed. Blue lines represent the interaction relationships between two proteins. DEG, differentially expressed genes.](MMR-16-04-4671-g00){#f1-mmr-16-04-4671}

![Subnetwork from the protein-protein interaction (PPI) network. Circles represent genes with high significance in the PPI network, and squares represent genes with low significance in the PPI network. Red nodes represent upregulated DEGs; green nodes represent downregulated DEGs; and pink nodes represent proteins with no significant expression change. Node color intensity was associated with the \|log2 fold-change\| of DEGs. DEG, differentially expressed gene.](MMR-16-04-4671-g01){#f2-mmr-16-04-4671}

###### 

Enriched KEGG pathways of the identified DEGs.

  DEG expression   KEGG pathway                          n    Example of identified genes                 P-value
  ---------------- ------------------------------------- ---- ------------------------------------------- --------------
  Downregulated    *Staphylococcus aureus* infection     16   *ITGB2, FPR1, FPR3, HLA-DRB3, ITGAM*        1.13×10^−15^
                   Phagosome                             17   *ITGB2, CORO1A, DRB1, HLA-DMB, COMP*        6.96×10^−13^
                   Allograft rejection                   10   *CD80, CD86, HLA-DMB, HLA-DQA1, HLA-DQA2*   5.97×10^−12^
                   Cell adhesion molecules               15   *CD4, CD80, ITGB2, CD86, HLA-DMB*           1.54×10^−11^
                   Graft-versus-host disease             10   *CD80, CD86, HLA-DMB, HLA-DQA1, HLA-DQA2*   1.85×10^−11^
                   Osteoclast differentiation            10   *LCP2, LILRB1, TYROBP, SPI1, BLNK*          1.70×10^−06^
                   Hematopoietic cell lineage            5    *CD4, HLA-DRA, HLA-DRB1, HLA-DRB3, ITGAM*   3.35×10^−03^
  Upregulated      Endometrial cancer                    3    *EGFR, TCF7L1, TCF7L2*                      2.25×10^−03^
                   Colorectal cancer                     3    *MSH6, TCF7L1, TCF7L2*                      3.72×10^−03^
                   Complement and coagulation cascades   3    *CFD, PROS1, TFPI*                          5.03×10^−03^
                   Adherens junction                     3    *EGFR, TCF7L1, TCF7L2*                      5.89×10^−03^
                   Thyroid cancer                        2    *TCF7L1, TCF7L2*                            9.41×10^−03^

DEG, differentially expressed gene; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

GO term functional enrichment of DEGs.

  DEG expression   GO ID        GO term                                       n    P-value
  ---------------- ------------ --------------------------------------------- ---- --------------
  Downregulated    GO:0002253   Activation of immune response                 38   1.26×10^−25^
                   GO:0050900   Leukocyte migration                           32   3.43×10^−21^
                   GO:0071345   Cellular response to cytokine stimulus        40   2.31×10^−18^
                   GO:0002696   Positive regulation of leukocyte activation   29   3.33×10^−16^
                   GO:0006954   Inflammatory response                         41   1.78×10^−15^
                   GO:0060326   Cell chemotaxis                               20   1.41×10^−11^
                   GO:0009306   Protein secretion                             21   4.17×10^−11^
                   GO:0009615   Response to virus                             25   4.29×10^−11^
                   GO:0007155   Cell adhesion                                 48   2.83×10^−10^
                   GO:0071222   Cellular response to lipopolysaccharide       15   7.00×10^−10^
  Upregulated      GO:0035265   Organ growth                                  6    9.06×10^−06^
                   GO:0031644   Regulation of neurological system process     8    1.85×10^−05^
                   GO:0033002   Muscle cell proliferation                     6    2.01×10^−05^
                   GO:0006790   Sulfur compound metabolic process             8    3.65×10^−05^
                   GO:0050678   Regulation of epithelial cell proliferation   7    1.17×10^−04^
                   GO:0009888   Tissue development                            19   1.49×10^−04^
                   GO:0007420   Brain development                             10   4.07×10^−04^
                   GO:0051893   Regulation of focal adhesion assembly         3    4.45×10^−04^
                   GO:0032355   Response to estradiol stimulus                4    5.27×10^−04^
                   GO:0019530   Taurine metabolic process                     2    5.05×10^−01^

DEG, differentially expressed gene; GO ID, gene ontology.

###### 

Functional annotation of the identified DEGs.

  DEG expression   TF count   TF                                            TAG count   TAG
  ---------------- ---------- --------------------------------------------- ----------- ----------------------------------------------------------------------------------------------------------
  Downregulated    3          *SPI1, PBX3, LEF1*                            12          ONCO: *WISP1, SPI1, HCK*
                                                                                        TS: *WNT5A, TP53INP1, MMP11, GJB2, ENC1, CAPG*
                                                                                        OTHER: *PBX3, EVI2B, CTSZ*
  Upregulated      6          *TCF7L2, PLAGL1*, *NFIA, IRF1, EGR2, CEBPD*   17          ONCO: *EGFR*
                                                                                        TS: *TGFBR3, TCF7L2, TCEAL7, SRPX, SPRY2, SFRP1, PLAGL1, NDRG2, IRF1, GPC3, EGR2, EEF1A1, CRABP1, CEBPD*
                                                                                        OTHER: *MSH6, CCL2*

ONCO, oncogene; TAG, tumor-associated gene; TF, transcription factor; TS, tumor suppressor.

###### 

KEGG enriched pathway analysis for DEGs in the subnetwork.

  KEGG pathway                                n   P-value
  ------------------------------------------- --- --------------
  *Staphylococcus aureus* infection           9   2.86×10^−11^
  Osteoclast differentiation                  7   1.19×10^−05^
  Natural killer cell-mediated cytotoxicity   7   1.77×10^−05^
  Cell adhesion molecules                     6   1.58×1^−04^
  B cell receptor signaling pathway           4   1.18×10^−03^
  Antigen processing and presentation         4   1.24×10^−03^
  Systemic lupus erythematosus                5   1.49×10^−03^
  Rheumatoid arthritis                        4   2.41×10^−03^
  Fcγ receptor-mediated phagocytosis          4   2.72×10^−03^
  Chemokine signaling pathway                 5   6.19×10^−03^
  Neuroactive ligand-receptor interaction     6   6.48×10^−03^
  Complement and coagulation cascades         3   9.01×10^−03^
  Viral myocarditis                           3   9.44×10^−03^

DEG, differentially expressed gene; KEGG, Kyoto Encyclopedia of Genes and Genomes.
